Sitagliptin relieves diabetic nephropathy fibrosis via the MAPK/ERK signaling pathway

Minerva Endocrinol. 2020 Sep;45(3):273-275. doi: 10.23736/S0391-1977.20.03122-3. Epub 2020 Feb 18.
No abstract available

Publication types

  • Letter

MeSH terms

  • Animals
  • Collagen / metabolism
  • Diabetes Mellitus, Type 2 / complications
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / pathology*
  • Extracellular Matrix Proteins / metabolism
  • Fibrosis
  • Hypoglycemic Agents / therapeutic use*
  • Kidney / pathology
  • MAP Kinase Signaling System / drug effects*
  • Oxidative Stress
  • Rats
  • Signal Transduction
  • Sitagliptin Phosphate / therapeutic use*

Substances

  • Extracellular Matrix Proteins
  • Hypoglycemic Agents
  • Collagen
  • Sitagliptin Phosphate